Drug Profile
Ad 35K++
Alternative Names: Ad35K++Latest Information Update: 13 Sep 2023
Price :
$50
*
At a glance
- Originator PAI Life Sciences
- Class Antineoplastics; Recombinant proteins
- Mechanism of Action Complement system protein modulators; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Stem cell engraftment
Most Recent Events
- 13 Sep 2023 Discontinued - Preclinical for Cancer (Combination therapy) in USA (IV) (PAI Life Sciences pipeline, September 2023)
- 13 Sep 2023 Discontinued - Preclinical for Stem cell engraftment in USA (Extracorporeal) (PAI Life Sciences pipeline, September 2023)
- 28 Apr 2020 No recent reports of development identified for preclinical development in Cancer(Combination therapy) in USA (IV)